Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s Xinshidai Gastric Cancer Drug Launch Ends Imports From Japan

This article was originally published in PharmAsia News

Executive Summary

Shandong Xinshidai Pharmaceuticals, a subsidiary of Lunan Pharma Group announced March 18 the launch of Weikangda (tegafur, gimeracil, oteracil). Weikangda is developed in China by Xinshida to treat progressive and inoperable gastric cancer. The drug is marked in Japan by Taiho Pharmaceutical under the name TS-1. Chinese patients previously relied on the higher-cost imported drugs from Japan. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071155

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel